si: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Gross profit	25,145	16,184
General and administrative	18,736	11,033
Sales and marketing	16,430	10,182
Medical education	3,262	2,136
Research and development	4,514	2,989
Interest/other expense	-14,790	-13,702
Net loss	-32,587	-23,858
Depreciation and amortization	2,228	1,385
Amortization of debt discounts	190	126
Stock-based compensation expense	615	317
Realized (loss) on marketable securities	402	207
Change in fair value of warrant liabilities and series e purchase option	11,975	13,134
Change in fair value of convertible notes, net	2,216	-
Other	-166	-99
Trade accounts receivable	2,060	1,820
Inventory	5,403	3,126
Prepaid expenses	1,279	260
Accounts payable	1,789	982
Other current assets and liabilities	-2,723	-1,954
Net cash used in operating activities	-19,829	-11,274
Fixed asset purchases	5,126	2,311
Purchases of marketable securities	95,582	20,477
Sales of marketable securities	22,393	16,909
Net cash (used in) provided by investing activities	-78,315	-5,879
Proceeds from exercise of common stock options	688	151
Proceeds from exercise of preferred stock warrants	455	362
Proceeds from series e convertible preferred stock, net of issuance cost	39,508	39,553
Proceeds from the issuance of convertible notes, net of issuance costs	39,863	-
Payment of deferred ipo offering costs	-	1,982
Proceeds from ipo, net of commissions and issuance costs	66,441	-
Net cash provided by financing activities	146,955	38,084
Net change in cash for period	48,811	20,931
Cash and cash equivalents at beginning of period	6,123	-
Cash and cash equivalents at end of period	54,934	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

si: the cashflow